Bispecific Anti-TRAILR2 and Anti-CDH17 Binding Molecules for Cancer Treatment - EP3559040A2

Thu, 16 Apr 2026 08:37:38 +0000
Intellectual Property

The EPO published patent application EP3559040A2, filed by Boehringer Ingelheim International GmbH, covering bispecific binding molecules that simultaneously target TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) and CDH17 (cadherin 17) for the treatment of cancer. The patent application was published on April 8, 2026 and is classified under IPC categories C07K 16/28, A61K 39/395, A61P 35/00, and C12N 15/62. The application designates all EPO contracting states covering major European pharmaceutical markets.